{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Long GV"],"funding":["Cancer Institute NSW (Cancer Institute New South Wales)","Cancer Institute NSW","University of Sydney","Department of Health | National Health and Medical Research Council"],"pagination":["1557-1566"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12092302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(5)"],"pubmed_abstract":["Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many tumor types, particularly when used neoadjuvantly or as a first-line treatment, including in melanoma brain metastases, they have shown limited efficacy in patients with resected or recurrent GBM. The lack of efficacy has been attributed to the scarcity of tumor-infiltrating lymphocytes (TILs), an immunosuppressive tumor microenvironment and low tumor mutation burden typical of GBM tumors, plus exclusion of large molecules from the brain parenchyma. We hypothesized that upfront neoadjuvant combination immunotherapy, administered with disease in situ"],"journal":["Nature medicine"],"pubmed_title":["Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma."],"pmcid":["PMC12092302"],"funding_grant_id":["2021/CBG0002","2020/ECF1244","2020/ECF1153"],"pubmed_authors":["Gide TN","Hsiao E","Wilmott JS","Satgunaseelan L","Gonzalez M","Perry KA","Buckland ME","Diefenbach RJ","Back M","Grimmond SM","Rawson RV","Quek C","da Silva IP","Menzies AM","Rizos H","Shklovskaya E","Rasko JEJ","Wheeler H","Palendira U","Phan TG","Mao Y","Vergara IA","Vissers JHA","Bai X","Carlino MS","Reardon DA","Yeo D","Khasraw M","Long GV","Shivalingam B","Drummond J","Neyns B","Caixeiro N","Ashley DM","Scolyer RA"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.","description":"Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many tumor types, particularly when used neoadjuvantly or as a first-line treatment, including in melanoma brain metastases, they have shown limited efficacy in patients with resected or recurrent GBM. The lack of efficacy has been attributed to the scarcity of tumor-infiltrating lymphocytes (TILs), an immunosuppressive tumor microenvironment and low tumor mutation burden typical of GBM tumors, plus exclusion of large molecules from the brain parenchyma. We hypothesized that upfront neoadjuvant combination immunotherapy, administered with disease in situ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T10:22:25.727Z","creation":"2026-04-08T11:22:49.999Z"},"accession":"S-EPMC12092302","cross_references":{"pubmed":["40016450"],"doi":["10.1038/s41591-025-03512-1"]}}